Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Aug 17;83(6):782–791. doi: 10.1054/bjoc.2000.1326

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines

D A Tonetti 1, M J Chisamore 1, W Grdina 1, H Schurz 1, V C Jordan 1
PMCID: PMC2363523  PMID: 10952784

Abstract

An inverse relationship between protein kinase C (PKC) activity and oestrogen receptor (ER) expression in human breast cell lines and tumours has been firmly established over the past 10 years. To determine whether specific alterations in PKC expression accompany hormone-independence, we examined the expression of PKC isozymes in the hormone-independent human breast cancer cell clones MCF-7 5C and T47D:C42 compared with their hormone-dependent counterparts, MCF-7 A4, MCF-7 WS8 and T47D:A18 respectively. Both hormone-independent cell clones exhibit elevated PKCα expression and increased basal AP-1 activity compared with the hormone-dependent cell clones. To determine whether PKCα overexpression is sufficient to mediate the hormone-independent phenotype, we stably transfected an expression plasmid containing PKCα cDNA to the T47D:A18 and MCF-7 A4 cell lines. This is the first report of PKCα transfection in T47D cells. In contrast to MCF-7 cells, T47D has the propensity to lose the ER and more readily forms tamoxifen-stimulated tumours in athymic mice. We find that in T47D:A18/PKCα clones, there is concomitant up-regulation of PKC βI and δ, whereas in the MCF-7 A4/PKCα transfectants PKC ɛ is up-regulated. In T47D:A18, but not in MCF-7 A4, PKCα stable transfection is accompanied by down-regulation of ER function whilst basal AP-1 activity is elevated. Our results suggest PKCα overexpression may play a role in growth signalling during the shift from hormone dependent to hormone-independent breast cancers. © 2000 Cancer Research Campaign

Keywords: breast cancer, protein kinase C, tamoxifen resistance, AP-1, hormone-independent

Full Text

The Full Text of this article is available as a PDF (1.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angel P., Baumann I., Stein B., Delius H., Rahmsdorf H. J., Herrlich P. 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol. 1987 Jun;7(6):2256–2266. doi: 10.1128/mcb.7.6.2256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Angel P., Imagawa M., Chiu R., Stein B., Imbra R. J., Rahmsdorf H. J., Jonat C., Herrlich P., Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 1987 Jun 19;49(6):729–739. doi: 10.1016/0092-8674(87)90611-8. [DOI] [PubMed] [Google Scholar]
  3. Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129–157. doi: 10.1016/0304-419x(91)90011-9. [DOI] [PubMed] [Google Scholar]
  4. Astruc M. E., Chabret C., Bali P., Gagne D., Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology. 1995 Mar;136(3):824–832. doi: 10.1210/endo.136.3.7867590. [DOI] [PubMed] [Google Scholar]
  5. Borner C., Wyss R., Regazzi R., Eppenberger U., Fabbro D. Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer. 1987 Sep 15;40(3):344–348. doi: 10.1002/ijc.2910400310. [DOI] [PubMed] [Google Scholar]
  6. Catherino W. H., Jordan V. C. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett. 1995 May 25;92(1):39–47. doi: 10.1016/0304-3835(95)03755-l. [DOI] [PubMed] [Google Scholar]
  7. Chen T. K., Smith L. M., Gebhardt D. K., Birrer M. J., Brown P. H. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar;15(3):215–226. doi: 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  8. Dekker L. V., Parker P. J. Protein kinase C--a question of specificity. Trends Biochem Sci. 1994 Feb;19(2):73–77. doi: 10.1016/0968-0004(94)90038-8. [DOI] [PubMed] [Google Scholar]
  9. Dumont J. A., Bitonti A. J., Wallace C. D., Baumann R. J., Cashman E. A., Cross-Doersen D. E. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 1996 Mar;7(3):351–359. [PubMed] [Google Scholar]
  10. Encarnación C. A., Ciocca D. R., McGuire W. L., Clark G. M., Fuqua S. A., Osborne C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993;26(3):237–246. doi: 10.1007/BF00665801. [DOI] [PubMed] [Google Scholar]
  11. Gordge P. C., Hulme M. J., Clegg R. A., Miller W. R. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer. 1996 Nov;32A(12):2120–2126. doi: 10.1016/s0959-8049(96)00255-9. [DOI] [PubMed] [Google Scholar]
  12. Hata A., Akita Y., Suzuki K., Ohno S. Functional divergence of protein kinase C (PKC) family members. PKC gamma differs from PKC alpha and -beta II and nPKC epsilon in its competence to mediate-12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive transcriptional activation through a TPA-response element. J Biol Chem. 1993 Apr 25;268(12):9122–9129. [PubMed] [Google Scholar]
  13. Jiang S. Y., Wolf D. M., Yingling J. M., Chang C., Jordan V. C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol. 1992 Dec;90(1):77–86. doi: 10.1016/0303-7207(92)90104-e. [DOI] [PubMed] [Google Scholar]
  14. Johnson M. D., Torri J. A., Lippman M. E., Dickson R. B. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp Cell Res. 1999 Feb 25;247(1):105–113. doi: 10.1006/excr.1998.4336. [DOI] [PubMed] [Google Scholar]
  15. Johnston S. R., Haynes B. P., Sacks N. P., McKinna J. A., Griggs L. J., Jarman M., Baum M., Smith I. E., Dowsett M. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat. 1993 Dec;28(3):241–250. doi: 10.1007/BF00666585. [DOI] [PubMed] [Google Scholar]
  16. Johnston S. R., Lu B., Scott G. K., Kushner P. J., Smith I. E., Dowsett M., Benz C. C. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res. 1999 Feb;5(2):251–256. [PubMed] [Google Scholar]
  17. Karnik P. S., Kulkarni S., Liu X. P., Budd G. T., Bukowski R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994 Jan 15;54(2):349–353. [PubMed] [Google Scholar]
  18. Kazanietz M. G., Areces L. B., Bahador A., Mischak H., Goodnight J., Mushinski J. F., Blumberg P. M. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol. 1993 Aug;44(2):298–307. [PubMed] [Google Scholar]
  19. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980 Mar 1;102(2):344–352. doi: 10.1016/0003-2697(80)90165-7. [DOI] [PubMed] [Google Scholar]
  20. Lee W., Mitchell P., Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell. 1987 Jun 19;49(6):741–752. doi: 10.1016/0092-8674(87)90612-x. [DOI] [PubMed] [Google Scholar]
  21. Manni A., Buckwalter E., Etindi R., Kunselman S., Rossini A., Mauger D., Dabbs D., Demers L. Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression. Cell Growth Differ. 1996 Sep;7(9):1187–1198. [PubMed] [Google Scholar]
  22. Martin M. B., Garcia-Morales P., Stoica A., Solomon H. B., Pierce M., Katz D., Zhang S., Danielsen M., Saceda M. Effects of 12-O-tetradecanoylphorbol-13-acetate on estrogen receptor activity in MCF-7 cells. J Biol Chem. 1995 Oct 20;270(42):25244–25251. doi: 10.1074/jbc.270.42.25244. [DOI] [PubMed] [Google Scholar]
  23. Morse-Gaudio M., Connolly J. M., Rose D. P. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol. 1998 Jun;12(6):1349–1354. doi: 10.3892/ijo.12.6.1349. [DOI] [PubMed] [Google Scholar]
  24. Ng T., Shima D., Squire A., Bastiaens P. I., Gschmeissner S., Humphries M. J., Parker P. J. PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J. 1999 Jul 15;18(14):3909–3923. doi: 10.1093/emboj/18.14.3909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992 Oct 23;258(5082):607–614. doi: 10.1126/science.1411571. [DOI] [PubMed] [Google Scholar]
  26. Nordeen S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques. 1988 May;6(5):454–458. [PubMed] [Google Scholar]
  27. O'Brian C., Vogel V. G., Singletary S. E., Ward N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 1989 Jun 15;49(12):3215–3217. [PubMed] [Google Scholar]
  28. Osborne C. K. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):83–89. doi: 10.1016/0960-0760(93)90060-a. [DOI] [PubMed] [Google Scholar]
  29. Philips A., Chalbos D., Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem. 1993 Jul 5;268(19):14103–14108. [PubMed] [Google Scholar]
  30. Pink J. J., Bilimoria M. M., Assikis J., Jordan V. C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer. 1996 Oct;74(8):1227–1236. doi: 10.1038/bjc.1996.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pink J. J., Jiang S. Y., Fritsch M., Jordan V. C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 1995 Jun 15;55(12):2583–2590. [PubMed] [Google Scholar]
  32. Platet N., Prévostel C., Derocq D., Joubert D., Rochefort H., Garcia M. Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer. 1998 Mar 2;75(5):750–756. doi: 10.1002/(sici)1097-0215(19980302)75:5<750::aid-ijc14>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  33. Reifel-Miller A. E., Conarty D. M., Valasek K. M., Iversen P. W., Burns D. J., Birch K. A. Protein kinase C isozymes differentially regulate promoters containing PEA-3/12-O-tetradecanoylphorbol-13-acetate response element motifs. J Biol Chem. 1996 Aug 30;271(35):21666–21671. doi: 10.1074/jbc.271.35.21666. [DOI] [PubMed] [Google Scholar]
  34. Saceda M., Knabbe C., Dickson R. B., Lippman M. E., Bronzert D., Lindsey R. K., Gottardis M. M., Martin M. B. Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem. 1991 Sep 25;266(27):17809–17814. [PubMed] [Google Scholar]
  35. Smith L. M., Wise S. C., Hendricks D. T., Sabichi A. L., Bos T., Reddy P., Brown P. H., Birrer M. J. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28;18(44):6063–6070. doi: 10.1038/sj.onc.1202989. [DOI] [PubMed] [Google Scholar]
  36. Sun X. G., Rotenberg S. A. Overexpression of protein kinase Calpha in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility. Cell Growth Differ. 1999 May;10(5):343–352. [PubMed] [Google Scholar]
  37. Tonetti D. A., Horio M., Collart F. R., Huberman E. Protein kinase C beta gene expression is associated with susceptibility of human promyelocytic leukemia cells to phorbol ester-induced differentiation. Cell Growth Differ. 1992 Oct;3(10):739–745. [PubMed] [Google Scholar]
  38. Tonetti D. A., Jordan V. C. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs. 1995 Aug;6(4):498–507. doi: 10.1097/00001813-199508000-00002. [DOI] [PubMed] [Google Scholar]
  39. Ways D. K., Kukoly C. A., deVente J., Hooker J. L., Bryant W. O., Posekany K. J., Fletcher D. J., Cook P. P., Parker P. J. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest. 1995 Apr;95(4):1906–1915. doi: 10.1172/JCI117872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Webb P., Lopez G. N., Uht R. M., Kushner P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 1995 Apr;9(4):443–456. doi: 10.1210/mend.9.4.7659088. [DOI] [PubMed] [Google Scholar]
  41. Wolf D. M., Jordan V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 1994;31(1):129–138. doi: 10.1007/BF00689683. [DOI] [PubMed] [Google Scholar]
  42. Wolf D. M., Langan-Fahey S. M., Parker C. J., McCague R., Jordan V. C. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst. 1993 May 19;85(10):806–812. doi: 10.1093/jnci/85.10.806. [DOI] [PubMed] [Google Scholar]
  43. Wyss R., Fabbro D., Regazzi R., Borner C., Takahashi A., Eppenberger U. Phorbol ester and epidermal growth factor receptors in human breast cancer. Anticancer Res. 1987 Jul-Aug;7(4B):721–727. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES